MX366935B - Peptidos intestinales vasoactivos modificados. - Google Patents

Peptidos intestinales vasoactivos modificados.

Info

Publication number
MX366935B
MX366935B MX2016004981A MX2016004981A MX366935B MX 366935 B MX366935 B MX 366935B MX 2016004981 A MX2016004981 A MX 2016004981A MX 2016004981 A MX2016004981 A MX 2016004981A MX 366935 B MX366935 B MX 366935B
Authority
MX
Mexico
Prior art keywords
vasoactive intestinal
vip
modified
intestinal peptides
modified vasoactive
Prior art date
Application number
MX2016004981A
Other languages
English (en)
Inventor
Sadeghi Homayoun
Turner Andrew
Dagher Suzanne
Original Assignee
Phasebio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phasebio Pharmaceuticals Inc filed Critical Phasebio Pharmaceuticals Inc
Publication of MX366935B publication Critical patent/MX366935B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a péptidos intestinales vasoactivos modificados (VIP) polinucleótidos y vectores codificantes, así como composiciones farmacéuticas que comprenden los mismos. La invención también proporciona métodos para fabricar y usar los agentes VIP modificados. De acuerdo con la invención, el VIP exhibe una semivida circulatoria prolongada, unión al receptor o potencia biológica y/o perfil de unión al receptor alterado con respecto al VIP sin modificar.
MX2016004981A 2009-08-14 2010-08-16 Peptidos intestinales vasoactivos modificados. MX366935B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23415109P 2009-08-14 2009-08-14
PCT/US2010/045605 WO2011020091A1 (en) 2009-08-14 2010-08-16 Modified vasoactive intestinal peptides

Publications (1)

Publication Number Publication Date
MX366935B true MX366935B (es) 2019-07-31

Family

ID=43586545

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016004981A MX366935B (es) 2009-08-14 2010-08-16 Peptidos intestinales vasoactivos modificados.
MX2012001979A MX339031B (es) 2009-08-14 2010-08-16 Peptidos intestinales vasoactivos modificados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012001979A MX339031B (es) 2009-08-14 2010-08-16 Peptidos intestinales vasoactivos modificados.

Country Status (19)

Country Link
US (4) US9029505B2 (es)
EP (2) EP3311828B1 (es)
JP (3) JP5801807B2 (es)
KR (2) KR101887009B1 (es)
CN (1) CN102596217B (es)
AU (3) AU2010282250B2 (es)
BR (1) BR112012003327A2 (es)
CA (1) CA2804755C (es)
DK (2) DK2464370T3 (es)
ES (2) ES2624478T3 (es)
HU (2) HUE032703T2 (es)
IL (1) IL218116A (es)
IN (1) IN2012DN02120A (es)
MX (2) MX366935B (es)
PL (2) PL3311828T3 (es)
PT (2) PT3311828T (es)
RU (1) RU2589255C2 (es)
SG (1) SG10201407329RA (es)
WO (1) WO2011020091A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
BR112012003327A2 (pt) * 2009-08-14 2017-06-06 Phasebio Pharmaceuticals Inc peptídeos intestinais vasoativos modificados
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
EP2747832A4 (en) * 2011-08-24 2015-01-07 Phasebio Pharmaceuticals Inc FORMULATIONS OF ACTIVE AGENTS FOR PROLONGED RELEASE
JP2014534265A (ja) * 2011-11-28 2014-12-18 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド インスリンアミノ酸配列を含む治療薬
US20150290328A1 (en) * 2012-11-20 2015-10-15 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
EP3139949B1 (en) * 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis
CN107206044A (zh) 2014-11-21 2017-09-26 费斯生物制药公司 用于受控且持续释放的elp融合蛋白
CN105753990B (zh) * 2014-12-19 2018-07-03 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
CN107427556B (zh) * 2015-02-09 2022-02-25 费斯生物制药公司 用于治疗肌肉疾病和病症的方法和组合物
WO2017152399A1 (zh) * 2016-03-09 2017-09-14 兰州大学 一种血管活性肠肽的融合蛋白及其制备方法和应用
MX2018013546A (es) 2016-05-06 2019-04-22 Phasebio Pharmaceuticals Inc Proteinas de fusion de elp para liberacion controlada y sostenida.
CN107056922A (zh) * 2016-12-24 2017-08-18 山东明鑫集团有限公司 一种具有降血糖作用的pacap多肽类似物的制备方法
WO2019240881A2 (en) * 2018-04-23 2019-12-19 Emory University Vip and vip agonists, nanoparticles, and uses in inflammatory t-cell mediated disease
KR102238519B1 (ko) * 2018-12-28 2021-04-13 (주)메디톡스 외래 단백질을 발현하는 미생물, 및 그의 용도
KR20210129516A (ko) * 2020-04-20 2021-10-28 주식회사 리비옴 혈관 작동성 장 펩티드를 발현하는 미생물, 및 그의 용도
US20230173030A1 (en) * 2020-05-05 2023-06-08 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
EP4326310A1 (en) 2021-04-20 2024-02-28 AdVita Lifescience AG Use of aviptadil alone or in combination with alpha lipoic acid as a therapeutic medicament for post-viral infection syndrome

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132746A (en) 1976-07-09 1979-01-02 University Of Alabama, Birmingham Medical & Education Foundation Synthetic elastomeric insoluble cross-linked polypentapeptide
US4187852A (en) 1976-07-09 1980-02-12 The University Of Alabama Synthetic elastomeric insoluble cross-linked polypentapeptide
US4474851A (en) 1981-10-02 1984-10-02 The University Of Alabama In Birmingham Elastomeric composite material comprising a polypeptide
US4500700A (en) 1981-10-02 1985-02-19 The Board Of Trustees Of The University Of Alabama For The University Of Alabama In Birmingham Elastomeric composite material comprising a polypentapeptide having an amino acid of opposite chirality in position three
US4589882A (en) 1983-09-19 1986-05-20 Urry Dan W Enzymatically crosslinked bioelastomers
US4752638A (en) 1983-11-10 1988-06-21 Genetic Systems Corporation Synthesis and use of polymers containing integral binding-pair members
US4749647A (en) 1984-06-22 1988-06-07 Genetic Systems Corporation Polymerization-induced separation assay using recognition pairs
US4605641A (en) 1984-10-09 1986-08-12 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4734400A (en) 1984-10-09 1988-03-29 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US4870055A (en) 1986-04-17 1989-09-26 University Of Alabama At Birmingham Segmented polypeptide bioelastomers to modulate elastic modulus
US4783523A (en) 1986-08-27 1988-11-08 Urry Dan W Temperature correlated force and structure development of elastin polytetrapeptides and polypentapeptides
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US4898926A (en) 1987-06-15 1990-02-06 The University Of Alabama At Birmingham/Research Foundation Bioelastomer containing tetra/penta-peptide units
US5514581A (en) 1986-11-04 1996-05-07 Protein Polymer Technologies, Inc. Functional recombinantly prepared synthetic protein polymer
US5773249A (en) 1986-11-04 1998-06-30 Protein Polymer Technologies, Inc. High molecular weight collagen-like protein polymers
US5496712A (en) 1990-11-06 1996-03-05 Protein Polymer High molecular weight collagen-like protein polymers
US5243038A (en) 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
US5830713A (en) 1986-11-04 1998-11-03 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US5770697A (en) 1986-11-04 1998-06-23 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6018030A (en) 1986-11-04 2000-01-25 Protein Polymer Technologies, Inc. Peptides comprising repetitive units of amino acids and DNA sequences encoding the same
US6184348B1 (en) 1986-11-04 2001-02-06 Protein Polymer Technologies Functional recombinantly prepared synthetic protein polymer
US5641648A (en) 1986-11-04 1997-06-24 Protein Polymer Technologies, Inc. Methods for preparing synthetic repetitive DNA
US4939224A (en) 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US4835252A (en) 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
US5606019A (en) 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
IL87055A (en) 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5234907A (en) * 1989-06-30 1993-08-10 Hoffmann-La Roche Inc. Synthetic vasoactive intestinal peptide analogs
US5141924A (en) 1989-06-30 1992-08-25 Hoffmann-La Roche, Inc. Synthetic vasoactive intestinal peptide analogs
US5236904A (en) 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
US5447912A (en) 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
ATE114458T1 (de) 1990-03-27 1994-12-15 Bioelastics Res Ltd Bioelastomeres arzneimittelabgabesystem.
DE69101187T2 (de) * 1990-06-26 1994-09-29 Sanwa Kagaku Kenkyusho Co VIP-Analogen und ihre Verwendung.
JPH07108232B2 (ja) * 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
US5235041A (en) 1990-12-28 1993-08-10 Protein Polymer Technologies, Inc. Purification of structurally ordered recombinant protein polymers
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5393602A (en) 1991-04-19 1995-02-28 Bioelastics Research Ltd. Superabsorbent materials and uses thereof
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
US5958881A (en) 1991-04-25 1999-09-28 Korman; Louis Y. Composition containing VIP for injection and a method of enhancing visualization of tissues during medical procedures
AU656230B2 (en) 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
US5681816A (en) 1992-04-24 1997-10-28 Korman; Louis Y. Method of inducing temporary paralysis of the gastrointestinal tract during medical procedure
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5972883A (en) 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
US5545617A (en) 1993-11-12 1996-08-13 The Schepens Eye Research Institute, Inc. Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5900405A (en) 1994-01-24 1999-05-04 Bioelastics Research, Ltd. Polymers responsive to electrical energy
WO1995027496A1 (en) 1994-04-07 1995-10-19 Proteinix Company Vasoactive intestinal polypeptide
US5527610A (en) 1994-05-20 1996-06-18 The Uab Research Foundation Elastomeric polypeptide matrices for preventing adhesion of biological materials
US5972406A (en) 1995-04-14 1999-10-26 Bioelastics Research Ltd. Bioelastomers suitable as food product additives
US5854387A (en) 1995-04-14 1998-12-29 Bioelastics Research, Ltd. Simple method for the purification of a bioelastic polymer
US6004782A (en) 1995-04-14 1999-12-21 Bioelastics Research Ltd. Hyperexpression of bioelastic polypeptides
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
DE69620898T2 (de) 1995-09-01 2002-11-07 University Of Washington, Seattle Interaktive molekulare konjugate
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
JP2000504676A (ja) 1996-02-09 2000-04-18 エフ・ホフマン―ラ ロシュ アーゲー Ｖｉｐアナログの合成
CA2243459C (en) 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
US6063061A (en) 1996-08-27 2000-05-16 Fusion Medical Technologies, Inc. Fragmented polymeric compositions and methods for their use
US5816259A (en) 1997-01-13 1998-10-06 Rose; Samuel Method for the diagnosis and treatment of cancer by the accumulation of radioactive precipitates in targeted cells
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043271A1 (en) 1998-02-27 1999-09-02 Bioelastics Research, Ltd. Injectable implants for tissue augmentation and restoration
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
US20020151458A1 (en) 1998-04-17 2002-10-17 Perez Gomariz Rosa Maria Method for treating and preventing septic shock with VPAC1R, VPAC2R and PAC1R agonists
ES2138561B1 (es) 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
WO2000056774A1 (en) 1999-03-19 2000-09-28 Duke University Methods of using bioelastomers
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
EP1233811A2 (en) 1999-11-12 2002-08-28 Leo Rubin Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use
US6235264B1 (en) 1999-12-01 2001-05-22 General Electric Company Medical imaging method for characterizing tumor angiogenesis using polymeric contrast agents
US6593394B1 (en) 2000-01-03 2003-07-15 Prosperous Kingdom Limited Bioactive and osteoporotic bone cement
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2001060862A1 (en) 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
US6608174B1 (en) 2000-02-18 2003-08-19 Dabur Research Foundation Radiolabeled vasoactive intestinal peptide analogs for diagnosis and radiotherapy
US6852834B2 (en) 2000-03-20 2005-02-08 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
US20050255554A1 (en) * 2000-03-20 2005-11-17 Ashutosh Chilkoti Fusion peptides isolatable by phase transition
EP1294757B1 (en) 2000-06-16 2006-11-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2002000149A1 (en) 2000-06-23 2002-01-03 Drexel University Polymeric, fiber matrix delivery systems for bioactive compounds
WO2002043746A2 (en) 2000-11-28 2002-06-06 Mondobiotech Sa Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension
CA2716959A1 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
WO2003039577A1 (fr) 2001-11-06 2003-05-15 Senju Pharmaceutical Co., Ltd. Remedes contre l'oeil sec et des maladies associees a l'oeil sec
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
ATE425763T1 (de) 2002-06-10 2009-04-15 Mondobiotech Licensing Out Ag Verwendung von zusammensetzungen mit der biologischen aktivitat der vasoaktiven intestinalen peptide zur behandlung von sarcoidose
CN100381462C (zh) 2002-11-27 2008-04-16 伊藤火腿株式会社 肽及含有所述肽的药物组合物
EP1633382A4 (en) 2003-05-14 2009-08-05 Dow Corning REPEAT SEQUENCE PROTEIN-POLYMER-ACTIVE CONJUGATE, METHOD AND USES
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
CN1917898B (zh) 2003-07-14 2011-08-17 盟多生化股份公司 用于治疗间质肺部感染的血管活性肠肽的生物活性物质
WO2005014030A1 (en) 2003-07-24 2005-02-17 Lutz-Henning Block Method for treating lung diseases associated with ventilation-perfusion mismatches
US7928059B2 (en) 2004-02-24 2011-04-19 Wisconsin Alumni Research Foundation Use of neuropeptides for traumatic cartilage injury
US7776815B2 (en) 2004-02-24 2010-08-17 Wisconsin Alumni Research Foundation Use of neuropeptides for ligament healing
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
AU2005231342A1 (en) 2004-03-29 2005-10-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Amphipathic glycopeptides
CA2567635A1 (en) * 2004-05-21 2005-12-01 Eli Lilly And Company Selective vpac2 receptor peptide agonists
WO2005120545A1 (en) 2004-06-11 2005-12-22 Vectus Biosystems Limited Compositions and methods for treatment of cardiovascular disease
WO2005123109A2 (en) 2004-06-12 2005-12-29 Bayer Pharmaceuticals Corporation Pegylation of vasoactive intestinal peptide (vip)/pituitary adenylate cyclase activating peptide (pacap) receptor 2 (vpac2) agonists and methods of use
EP1781693A2 (en) * 2004-08-18 2007-05-09 Eli Lilly And Company Selective vpac2 receptor peptide agonists
US20080085860A1 (en) * 2004-08-18 2008-04-10 Eli Lilly And Company Selective Vpac2 Receptor Peptide Agonists
WO2006042152A2 (en) 2004-10-08 2006-04-20 Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals
US7723472B2 (en) 2005-02-28 2010-05-25 The Regents Of The University Of California Extracellular matrix binding chimeric proteins and methods of use thereof
CN101500606B (zh) 2005-06-24 2013-12-04 杜克大学 基于热反应生物聚合物的直接药物送递***
BRPI0617740A2 (pt) * 2005-10-26 2011-08-02 Lilly Co Eli agonistas seletivos peptìdicos do receptor vpac2, composição farmacêutica e uso dos referidos agonistas
WO2007057922A1 (en) * 2005-11-18 2007-05-24 Dabur Pharma Limited Targeted fusion proteins for cancer therapy
BRPI0620566B8 (pt) 2005-12-09 2021-05-25 Vectus Biosystems Ltd composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip
JP2009525946A (ja) * 2005-12-20 2009-07-16 デューク・ユニヴァーシティ 増強された薬理学的性質を有する活性物質を送達するための方法および組成物
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8367626B2 (en) * 2006-05-12 2013-02-05 Wisconsin Alumni Research Foundation Elastin-like polymer delivery vehicles
US20110039776A1 (en) 2006-09-06 2011-02-17 Ashutosh Chilkoti Fusion peptide therapeutic compositions
ES2373824T3 (es) 2007-05-21 2012-02-09 Res International Sarl Péptidos con propiedades mejoradas que tienen la actividad biológica del péptido intestinal vasoactivo (piv) y su uso para el tratamiento de enfermedades pulmonares.
US8933197B2 (en) 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
US20110288001A1 (en) * 2008-12-18 2011-11-24 Homayoun Sadeghi Biologically active proteins activatable by peptidase
BR112012003327A2 (pt) 2009-08-14 2017-06-06 Phasebio Pharmaceuticals Inc peptídeos intestinais vasoativos modificados
HUE047354T2 (hu) 2011-05-18 2020-04-28 Vertex Pharmaceuticals Europe Ltd Ivacaftor deuterizált származékai
WO2012170524A1 (en) 2011-06-06 2012-12-13 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
US9605186B2 (en) 2012-09-19 2017-03-28 Exxonmobil Chemical Patents Inc. Adhesive compositions of ethylene-based and propylene-based polymers
EP3139949B1 (en) 2014-05-08 2020-07-29 Phasebio Pharmaceuticals, Inc. Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis

Also Published As

Publication number Publication date
RU2012109553A (ru) 2013-09-20
US20110178017A1 (en) 2011-07-21
AU2016200897B2 (en) 2017-10-12
EP2464370B1 (en) 2017-03-29
US20240091313A1 (en) 2024-03-21
KR20120062777A (ko) 2012-06-14
CN102596217A (zh) 2012-07-18
JP2013501818A (ja) 2013-01-17
HUE032703T2 (en) 2017-10-30
US9029505B2 (en) 2015-05-12
DK2464370T3 (en) 2017-05-15
IL218116A0 (en) 2012-04-30
JP2016000751A (ja) 2016-01-07
MX2012001979A (es) 2012-06-25
ES2624478T3 (es) 2017-07-14
EP2464370A4 (en) 2013-03-27
US20180008677A1 (en) 2018-01-11
PT3311828T (pt) 2021-05-05
DK3311828T3 (da) 2021-06-28
RU2589255C2 (ru) 2016-07-10
CA2804755C (en) 2018-06-05
CA2804755A1 (en) 2011-02-17
JP5801807B2 (ja) 2015-10-28
SG10201407329RA (en) 2015-01-29
IL218116A (en) 2017-06-29
HUE054744T2 (hu) 2021-12-28
EP2464370A1 (en) 2012-06-20
CN102596217B (zh) 2014-07-02
MX339031B (es) 2016-05-05
JP2017066157A (ja) 2017-04-06
KR20170085611A (ko) 2017-07-24
AU2016200897A1 (en) 2016-03-03
AU2017279636B2 (en) 2019-09-12
EP3311828A1 (en) 2018-04-25
PL3311828T3 (pl) 2021-11-22
BR112012003327A2 (pt) 2017-06-06
PL2464370T3 (pl) 2017-08-31
US20160220642A1 (en) 2016-08-04
ES2870914T3 (es) 2021-10-28
JP6229038B2 (ja) 2017-11-08
US9700598B2 (en) 2017-07-11
AU2017279636A1 (en) 2018-01-18
IN2012DN02120A (es) 2015-08-21
KR101943420B1 (ko) 2019-04-17
PT2464370T (pt) 2017-05-17
JP6069441B2 (ja) 2017-02-01
KR101887009B1 (ko) 2018-08-09
EP3311828B1 (en) 2021-04-07
AU2010282250B2 (en) 2015-11-12
AU2010282250A1 (en) 2012-04-05
WO2011020091A1 (en) 2011-02-17

Similar Documents

Publication Publication Date Title
IN2012DN02120A (es)
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
MX348622B (es) Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
TW200716646A (en) (S)-N-methylnaltrexone
MX2010004374A (es) Armazones proteinicos.
EP2493506A4 (en) IL-17A ANTAGONISTS
WO2009126292A3 (en) Biologically active peptidomimetic macrocycles
MX2009005466A (es) Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
TN2010000213A1 (en) Wise binding antibodies and epitopes
MY156315A (en) Anti-vegf antibodies
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
MX2012005527A (es) Preparaciones que contienen el factor de von willebrand (fvw) procedimientos, kits y aplicaciones relacionados con las mismas.
PH12013502192A1 (en) Antibodies against human angiopoietin 2
BR112013032717A2 (pt) coagonistas do receptor de glucagon/glp-1
MY159135A (en) Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
NZ595361A (en) Chimeric factor h binding proteins (fhbp) and methods of use
MX359639B (es) Metodos y composiciones para uso en tratamientos celulares.
ATE501731T1 (de) Melanocortin-rezeptor-bindende mimetibodies, zusammensetzungen, verfahren und verwendungen
MY160560A (en) Compositions and methods for treatment of kidney disorders
MX2010005589A (es) Composicion para el cuidado personal.
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
MX2007006042A (es) Bengamidas que poseen un ciclo caprolactama sustituido, procedimiento de preparacion, composiciones que las contienen y utilizacion.